Karen LaRochelle is currently a Venture Partner with Advent Life Sciences and SVP. Corporate and Business Development for WindMIL Therapeutics. Her career has focused on strategy and collaborations for pharmaceutical and biotechnology companies in the US, Europe and China including strategic collaborations, M&A and out-licensing.
Prior, Karen served as CBO of PsiOxus Therapeutics and spent 20 years with Bristol-Myers Squibb serving as Global Head of Negotiations and Head of Business Development in China, following earlier positions in alliance management, strategy, analysis and finance. She was also the Principal of LaRochelle Advisors, LLC serving multiple biotechnology companies including Exelixis, Ovid Therapeutics, Otsuka and Chase Pharmaceuticals with business development and collaboration services.
Karen received her MBA from Columbia University and a BS in Industrial Engineering from Lehigh University. She leads the Business Development Advisory Board of New Jersey’s Biotechnology Council (BioNJ), and currently serves on the Lehigh University Engineering Advisory Board.
She previously served on the ISE Advisory Council from 2008 to 2011.
